Jill S. Clancy

3.6k total citations · 3 hit papers
27 papers, 2.2k citations indexed

About

Jill S. Clancy is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jill S. Clancy has authored 27 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Jill S. Clancy's work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Jill S. Clancy is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Jill S. Clancy collaborates with scholars based in United States, Italy and Australia. Jill S. Clancy's co-authors include Antonello Abbattista, Alice T. Shaw, Benjamin Solomon, Benjamin Besse, Todd M. Bauer, Jean‐François Martini, Enriqueta Felip, Anna Berkenblit, Leonard P. James and Holger Thurm and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Jill S. Clancy

27 papers receiving 2.1k citations

Hit Papers

Lorlatinib in non-small-cell lung cancer with... 2009 2026 2014 2020 2017 2009 2019 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
    2017 487 citations Alice T. Shaw, Enriqueta Felip et al. The Lancet Oncology profile →
  2. Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
    2009 485 citations Anna Berkenblit, Jill S. Clancy et al. Journal of Clinical Oncology profile →
  3. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
    2019 269 citations Alice T. Shaw, Benjamin Solomon et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jill S. Clancy United States 16 1.4k 1.2k 935 453 447 27 2.2k
Holger Thurm United States 19 1.7k 1.2× 1.4k 1.2× 624 0.7× 176 0.4× 470 1.1× 48 2.2k
Reimi Asaka Japan 13 1.1k 0.8× 875 0.7× 758 0.8× 369 0.8× 510 1.1× 17 1.8k
Cristian Massacesi Italy 20 1.1k 0.8× 1.6k 1.3× 984 1.1× 188 0.4× 288 0.6× 67 2.4k
Giancarlo Bisagni Italy 25 832 0.6× 1.9k 1.6× 570 0.6× 218 0.5× 747 1.7× 127 2.9k
Walter Bordogna Switzerland 22 2.1k 1.5× 1.8k 1.4× 827 0.9× 180 0.4× 584 1.3× 49 2.6k
Ali Zeaiter United States 19 3.2k 2.2× 2.8k 2.3× 999 1.1× 314 0.7× 750 1.7× 77 3.9k
V.A. Miller United States 22 1.6k 1.2× 2.1k 1.7× 924 1.0× 350 0.8× 508 1.1× 83 3.0k
Wael A. Harb United States 23 759 0.5× 1.4k 1.1× 923 1.0× 247 0.5× 423 0.9× 118 2.5k
Viola W. Zhu United States 30 2.1k 1.5× 1.7k 1.3× 1.0k 1.1× 283 0.6× 646 1.4× 83 2.6k
Eva Ciruelos Spain 15 1.4k 1.0× 1.5k 1.2× 924 1.0× 185 0.4× 936 2.1× 76 2.5k

Countries citing papers authored by Jill S. Clancy

Since Specialization
Citations

This map shows the geographic impact of Jill S. Clancy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jill S. Clancy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jill S. Clancy more than expected).

Fields of papers citing papers by Jill S. Clancy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jill S. Clancy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jill S. Clancy. The network helps show where Jill S. Clancy may publish in the future.

Co-authorship network of co-authors of Jill S. Clancy

This figure shows the co-authorship network connecting the top 25 collaborators of Jill S. Clancy. A scholar is included among the top collaborators of Jill S. Clancy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jill S. Clancy. Jill S. Clancy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Joseph, Alessandra Bearz, Dong‐Wan Kim, et al.. (2023). Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Pharmacokinetics. 63(2). 171–182. 3 indexed citations
2.
Schadendorf, Dirk, Reinhard Dummer, Caroline Robert, et al.. (2023). Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).. Journal of Clinical Oncology. 41(16_suppl). 9531–9531. 1 indexed citations
3.
Chen, Joseph, Ana Ruiz-Garcı́a, Leonard P. James, et al.. (2021). Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer. Clinical Pharmacology & Therapeutics. 110(5). 1273–1281. 16 indexed citations
4.
Peters, Solange, Alice T. Shaw, Benjamin Besse, et al.. (2020). Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer. 144. 10–19. 15 indexed citations
5.
Chen, Joseph, Alessandra Bearz, D. Kim, et al.. (2019). P1.01-84 Interaction of Lorlatinib with CYP2B6, CYP2C9, UGT, and P-gp Probe Drugs in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S392–S393. 2 indexed citations
6.
Shaw, Alice T., Benjamin Solomon, Rita Chiari, et al.. (2019). Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. The Lancet Oncology. 20(12). 1691–1701. 248 indexed citations
7.
Shaw, Alice T., Benjamin Solomon, Benjamin Besse, et al.. (2019). ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 37(16). 1370–1379. 269 indexed citations breakdown →
8.
Ou, S-H.I., Alice T. Shaw, G. Riely, et al.. (2018). OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6. Journal of Thoracic Oncology. 13(10). S322–S323. 16 indexed citations
9.
Besse, Benjamin, Benjamin Solomon, Enriqueta Felip, et al.. (2018). Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.. Journal of Clinical Oncology. 36(15_suppl). 9032–9032. 12 indexed citations
10.
Peters, Solange, Alice T. Shaw, Benjamin Besse, et al.. (2018). Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii504–viii505. 3 indexed citations
11.
Shaw, Alice T., Jean‐François Martini, Benjamin Besse, et al.. (2018). Abstract CT044: Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations. Cancer Research. 78(13_Supplement). CT044–CT044. 7 indexed citations
12.
Felip, Enriqueta, Todd M. Bauer, Benjamin Solomon, et al.. (2017). MA07.11 Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+ Non-Small-Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S383–S384. 14 indexed citations
13.
Besse, Benjamin, Alice T. Shaw, Benjamin Solomon, et al.. (2017). Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v465–v466. 1 indexed citations
14.
Shaw, Alice T., Enriqueta Felip, Todd M. Bauer, et al.. (2017). Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. The Lancet Oncology. 18(12). 1590–1599. 487 indexed citations breakdown →
15.
Shaw, Alice T., Sai‐Hong Ignatius Ou, Enriqueta Felip, et al.. (2017). Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.. Journal of Clinical Oncology. 35(15_suppl). 9006–9006. 21 indexed citations
16.
Solomon, Benjamin, Alice T. Shaw, Sai‐Hong Ignatius Ou, et al.. (2017). OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 12(11). S1756–S1756. 28 indexed citations
17.
Bauer, Todd M., Alice T. Shaw, Benjamin Solomon, et al.. (2015). Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations.. Journal of Clinical Oncology. 33(15_suppl). TPS2620–TPS2620. 10 indexed citations
18.
19.
Geoerger, Birgit, Mark W. Kieran, Stephan A. Grupp, et al.. (2011). Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. European Journal of Cancer. 48(2). 253–262. 103 indexed citations
20.
Spunt, Sheri L., Stephan A. Grupp, Terry A. Vik, et al.. (2011). Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors. Journal of Clinical Oncology. 29(21). 2933–2940. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Holger Thurm Breakdown of academic impact, for papers by Reimi Asaka Breakdown of academic impact, for papers by Cristian Massacesi Breakdown of academic impact, for papers by Giancarlo Bisagni Breakdown of academic impact, for papers by Walter Bordogna Breakdown of academic impact, for papers by Ali Zeaiter Breakdown of academic impact, for papers by V.A. Miller Breakdown of academic impact, for papers by Wael A. Harb Breakdown of academic impact, for papers by Viola W. Zhu Breakdown of academic impact, for papers by Eva Ciruelos
Rankless by CCL
2026